Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.
about
The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancerRecent Advancements of Treatment for Leptomeningeal CarcinomatosisRe-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired ResistanceSystemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.Downregulation of EGFR in a metastatic brain lesion of EGFR-mutated non-small cell lung cancer using a tyrosine kinase inhibitor: A case reportCurrent approaches to the treatment of metastatic brain tumours.Nasogastric tube-administered alectinib achieved long-term survival in a crizotinib-refractory nonsmall cell lung cancer patient with a poor performance statusProtein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activationRandomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastasesGood Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene MutationNear Total Regression of Diffuse Brain Metastases in Adenocarcinoma of the Lung with an EGFR Exon 19 Mutation: A Case Report and Review of the LiteratureEGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond ProgressionErlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature.Long-term survival of a patient with carcinomatous meningitis due to non-small cell lung cancer treated with erlotinib following gefitinib.Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation.Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases.Treatment and prognostic analysis of patients with leptomeningeal metastases from non-small cell lung cancer.Recurrent response to advanced lung adenocarcinoma with erlotinib developing leptomeningeal metastases during gefitinib therapy and two case reports.Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastasesCarcinomatous meningitis: Leptomeningeal metastases in solid tumorsEvaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal FluidPeritoneal and meningeal relapse from lung adenocarcinoma after a response to gefitinib: A case report.Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: Two Case Reports.A Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer.Therapy and prophylaxis of brain metastases.Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera?Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation.EGFR mutation status in brain metastases of non-small cell lung carcinoma.Complete Remission of Brain Metastases in Non-Small Cell Lung Cancer Patients Harboring an EGFR Mutation Treated with Tyrosine Kinase Inhibitor without Radiotherapy: A Report of 3 Cases.Oral Targeted Therapies and Central Nervous System (CNS) Metastases.Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future.Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?Effect of chemotherapy on survival after whole brain radiation therapy for brain metastases: a single-center retrospective analysis.Retrospective analysis of survival in patients with leptomeningeal carcinomatosis from lung adenocarcinoma treated with erlotinib and gefitinib.EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases.Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung disease.
P2860
Q26740529-DF95AE47-0071-4ABE-971F-96E7A3706857Q26798009-CAD788D3-4204-40D8-BB3F-A5145D9259C9Q28083239-4E5F3434-C1A6-474F-A5C8-72B511FB7BECQ30239901-01E949B5-A930-4C48-997F-C174ED0CA330Q30438136-B6E6F37F-40CF-46E9-966F-F9B5E6896836Q33597567-1EE7E867-0C1E-438E-B357-A014BA8931FFQ33696559-453B0B4F-145D-4F84-86FD-270F45C18E40Q33760992-F8BD74BC-5F4B-423D-8626-C8B7FD342884Q33901255-C105309A-C266-44A5-B873-83F0BDC3B3E4Q33958338-D848C913-EA58-4598-9046-935867C26646Q34059536-448EDB09-24BB-4C38-82E1-28B371229196Q34075381-8E9E2C3F-EE8B-4A07-BBD9-2F3BD1B51BDCQ34650994-CAC6502B-489E-4F90-829E-5E152B8522A1Q34657690-4D43ECFE-7EB3-4C12-8A14-E270F7E56695Q35222304-BD4C71ED-D136-4D7E-B874-E23806B7B3EAQ35233470-63615355-B829-4FAA-A787-558FB9E4842AQ35623614-BAB69352-C4E7-4528-90EE-8471D33D0483Q35879370-860DA960-B361-4C2A-8A9F-120DB71934E0Q36439260-BB5DE2C7-3DE0-4643-9E0D-0D3AB72264F9Q36660669-40C3837E-BCCE-470E-9340-318A8AD30B72Q36833970-3E43A1F7-FFFC-4108-8337-6D08A0453BBDQ36851197-E30DC7BF-C144-4CBE-86B7-8D86C9D4B571Q37168845-E4EB7447-81C5-4250-AE72-45FE19029055Q37560791-033C6509-DDBE-430A-B449-D71E26F654D2Q37646729-9DFE47C3-02DE-418C-B222-72AD6E20219DQ37742623-603ED292-FE4B-4C92-B1FF-F1C294D74412Q37809862-A5388001-D8E3-4242-8B4E-9D0BB9BCDF73Q37870216-87A3CEE4-E335-4B4F-854D-7A22C1851D88Q38019974-BAF25661-308F-4E6F-BCC8-849A1116AE08Q38053963-8BA4E8B1-9652-434B-8062-D39E733BE619Q38616033-D41AEAB1-1DDD-4B71-8417-984EBD668C9CQ38631975-46E755E5-E29D-4A19-8DAC-B0F405B1F79BQ38763111-CB15EBE2-300E-4AFC-AE91-42AC603A265EQ38821038-5FBAFB2E-0AC2-44C0-9048-C4637A9A7302Q39637384-96BF8C93-A645-4FC2-9EF9-5552DF1DABC2Q40381138-76080BC6-D3CB-43DE-B3DF-CDC01067F27CQ40414834-FD71CBB9-64DE-4CC8-89DA-57A9859CE76AQ40498874-8F5C80C5-F9F0-4A0F-B418-A90285DC0631Q43611330-8BA92FB7-E8AC-42F4-93C6-40AF078BC980Q44466124-309E926A-A672-4E28-9302-A76A3029EFE2
P2860
Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Efficacy of erlotinib for brai ...... al good response to gefitinib.
@en
Efficacy of erlotinib for brai ...... al good response to gefitinib.
@nl
type
label
Efficacy of erlotinib for brai ...... al good response to gefitinib.
@en
Efficacy of erlotinib for brai ...... al good response to gefitinib.
@nl
prefLabel
Efficacy of erlotinib for brai ...... al good response to gefitinib.
@en
Efficacy of erlotinib for brai ...... al good response to gefitinib.
@nl
P2093
P50
P1476
Efficacy of erlotinib for brai ...... al good response to gefitinib.
@en
P2093
Junichi Shimizu
Ryoichi Onozato
Shunzo Hatooka
Taijiro Sueda
Takayuki Fukui
Tatsuya Katayama
Toyoaki Hida
P304
P356
10.1097/JTO.0B013E3181B62572
P577
2009-11-01T00:00:00Z